Business Context and Reporting Period
This is Brooks Automation, Inc.’s unaudited Form 10-Q for the quarter and six months ended March 31, 2016, filed April 28, 2016. The request identifies Azenta, Inc.; however, the filing itself identifies the registrant as Brooks Automation, Inc. Brooks operated through Product Solutions, Global Services, and Life Science Systems segments, serving semiconductor capital equipment and life-science sample-management markets.
Financial Highlights
| Metric | Three months ended March 31, 2016 | Six months ended March 31, 2016 |
|---|---|---|
| Revenue | $135.3 million | $255.2 million |
| Gross profit | $46.8 million | $87.4 million |
| Gross margin | 34.6% | 34.2% |
| Operating income (loss) | $(6.3) million | $(14.7) million |
| Net income (loss) | $(83.9) million | $(88.6) million |
| Diluted EPS | $(1.22) | $(1.30) |
| Operating cash flow | Not separately provided for the quarter | $0.4 million |
- Product revenue declined year over year, while services revenue increased. Six-month product revenue was $190.6 million and services revenue was $64.6 million.
- Cash and cash equivalents were $62.2 million at March 31, 2016, compared with $80.7 million at September 30, 2015. Total cash, cash equivalents, and marketable securities were $68.3 million, down from $214.0 million.
- Total assets were $684.4 million and total liabilities were $146.4 million. The filing does not show material outstanding borrowings; management expected to secure a revolving credit facility with more than $50 million of initial borrowing capacity.
- Capital expenditures were $6.1 million for the six-month period, dividends paid were $13.7 million, and cash used for acquisitions was $125.5 million.
Material Changes Versus the Prior Comparable Period
- Revenue decreased 3% for both the quarter and six-month period, from $139.3 million to $135.3 million and from $262.0 million to $255.2 million, respectively.
- Product Solutions revenue declined $12.2 million in the quarter and $18.5 million in the six-month period, reflecting lower robotic automation, cryogenic, refrigerant-system, and contamination-control sales.
- Life Science Systems revenue increased to $26.5 million in the quarter and $47.3 million for six months, primarily due to the BioStorage acquisition, completed November 30, 2015. BioStorage contributed $11.4 million of quarterly revenue and $17.9 million of six-month revenue.
- Gross margin improved from 33.0% to 34.6% for the quarter and from 32.5% to 34.2% for six months, driven principally by Life Science Systems and Product Solutions improvements.
- Operating results deteriorated because restructuring charges increased to $7.3 million for the quarter and $8.8 million for six months, compared with $0.7 million and $3.4 million, respectively.
- The company recorded a $78.2 million quarterly income-tax provision and a $74.9 million six-month provision, primarily from establishing a full valuation allowance against U.S. net deferred tax assets. This drove most of the reported net loss.
- Goodwill increased to $202.3 million from $121.4 million, primarily from the BioStorage acquisition. Intangible assets increased to $89.5 million from $55.4 million.
Guidance, Outlook, Risks, and Unusual Items
- Management projected a net loss for full fiscal 2016 following the second-quarter loss and restructuring actions.
- A company-wide restructuring initiated in March 2016 was expected to generate approximately $13.5 million of annual pretax savings, including $4.5 million in cost of revenue, $2.7 million in research and development, and $6.3 million in selling, general and administrative expense. Savings were expected to begin in the third quarter of fiscal 2016, with substantial completion by June 30, 2016.
- Management expected approximately $13.1 million of annual cash-spending reduction from the restructuring. Accrued restructuring liabilities were $7.4 million at March 31, 2016 and were expected to be paid within twelve months.
- Semiconductor demand and capital-equipment spending remain cyclical and can fluctuate materially by quarter. Management noted declining operating trends and forecasts at the Polycold reporting unit; a goodwill impairment test found fair value exceeded carrying value by 18%, so no impairment was recorded.
- Management expected continued Life Science Systems growth from internally developed products, including Twin-bank and Biostore III systems, and from acquisitions, but stated that projected future profits were not sufficiently supported by objective bookings or backlog evidence to justify reversing the U.S. deferred-tax valuation allowance.
- Foreign-exchange exposure is significant: 63% of quarterly revenue and 62% of six-month revenue came from outside the United States. A hypothetical 10% currency-rate change would have changed net loss by approximately $0.3 million.
- Letters of credit totaled approximately $3.6 million, primarily supporting customer advances and performance obligations. No letters had been called.
- One customer represented approximately 10% of quarterly and six-month revenue. The filing states that ordinary-course legal proceedings were not expected to have a material effect, but outcomes remain uncertain.
- The Board declared a subsequent quarterly dividend of $0.10 per share, or approximately $6.9 million, payable June 24, 2016.
Most Important Facts for Investors to Verify
- Confirm the issuer identity: the supplied filing is for Brooks Automation, Inc., not Azenta, Inc.
- Assess the sustainability of liquidity after the $125.5 million BioStorage acquisition, dividends, capital expenditures, and the reduction in marketable securities.
- Evaluate whether the announced restructuring produces the projected annual savings and whether execution or severance costs differ from estimates.
- Monitor semiconductor-market demand, Product Solutions revenue, Polycold forecasts, and the potential for future goodwill impairment.
- Separate the $79.3 million deferred-tax valuation-allowance charge from recurring operating performance and assess the conditions required for any future reversal.
- Review BioStorage integration, profitability, acquisition accounting, intangible-asset amortization, and remaining purchase-price-allocation estimates.
- Verify the planned revolving credit facility, its final terms, borrowing-base limitations, and any subsequent changes in dividend policy or liquidity.